Regulating the stem cell industry: needs and responsibilities.
作者信息
Lee Tsung-Ling, Lysaght Tamra, Lipworth Wendy, Hendl Tereza, Kerridge Ian, Munsie Megan, Stewart Cameron
机构信息
Centre for Biomedical Ethics, Clinical Research Centre, National University of Singapore, #02-03, 10 Medical Drive, 117597 Singapore.
Centre for Values, Ethics and the Law in Medicine, Sydney, University of Sydney, Australia.
出版信息
Bull World Health Organ. 2017 Sep 1;95(9):663-664. doi: 10.2471/BLT.16.189977. Epub 2017 Jul 1.
Abstract
摘要
相似文献
1
Regulating the stem cell industry: needs and responsibilities.规范干细胞产业：需求与责任
Bull World Health Organ. 2017 Sep 1;95(9):663-664. doi: 10.2471/BLT.16.189977. Epub 2017 Jul 1.
2
Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.行业在应对未经证实的干细胞疗法直接面向消费者的营销方面的责任。
Clin Pharmacol Ther. 2017 Aug;102(2):177-179. doi: 10.1002/cpt.704. Epub 2017 Jul 10.
3
Care and cultivation. Protestant thinking on biotechnology seeks a balance between freedom and responsibility.关怀与培育。新教对生物技术的思考寻求在自由与责任之间取得平衡。
Health Prog. 2002 Jan-Feb;83(1):34-8, 54.
4
Stem cell ethics and the forgotten corporate context.干细胞伦理与被遗忘的企业背景。
Am J Bioeth. 2002 Winter;2(1):54-6. doi: 10.1162/152651602317267961.
5
Will stem cells create a market for human embryos?
J Androl. 2001 Jan-Feb;22(1):12.
6
Marketing of unproven stem cell-based interventions: A call to action.未经证实的基于干细胞的干预措施的营销：行动呼吁。
Sci Transl Med. 2017 Jul 5;9(397). doi: 10.1126/scitranslmed.aag0426.
7
The marketing potential of corporate social responsibility activities: the case of the alcohol industry in Latin America and the Caribbean.企业社会责任活动的营销潜力：以拉丁美洲和加勒比地区的酒精行业为例。
Addiction. 2017 Jan;112 Suppl 1:74-80. doi: 10.1111/add.13616.
8
Ethical and legal issues in technology: xenotransplantation.技术中的伦理与法律问题：异种移植
Am J Law Med. 2001;27(2-3):283-300.
9
Industrial Biotechnology: To What Extent Is Responsible Innovation on the Agenda?工业生物技术：负责任的创新在议程上占据何种程度？
Trends Biotechnol. 2020 Jan;38(1):5-7. doi: 10.1016/j.tibtech.2019.07.006. Epub 2019 Aug 6.
10
The protective oversight of biotechnology.
Biosecur Bioterror. 2004;2(4):273-80. doi: 10.1089/bsp.2004.2.273.
引用本文的文献
1
Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities.康复的 COVID-19 合并 COPD 和哮喘患者的即将出现的并发症；可能的治疗机会。
Cell Commun Signal. 2022 Nov 1;20(1):173. doi: 10.1186/s12964-022-00982-5.
2
Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment.用于糖尿病治疗的临床级人诱导多能干细胞衍生β细胞的制造。
Cell Prolif. 2022 Aug;55(8):e13232. doi: 10.1111/cpr.13232. Epub 2022 Apr 26.
3
Unproven stem cell interventions: A global public health problem requiring global deliberation.未经证实的干细胞干预措施：一个需要全球商讨的全球公共卫生问题。
Stem Cell Reports. 2021 Jun 8;16(6):1435-1445. doi: 10.1016/j.stemcr.2021.05.004.
4
Quality assurance and adverse event management in regenerative medicine for knee osteoarthritis: Current concepts.膝关节骨关节炎再生医学中的质量保证与不良事件管理：当前概念
J Clin Orthop Trauma. 2019 Jan-Feb;10(1):53-58. doi: 10.1016/j.jcot.2018.09.005. Epub 2018 Sep 18.
本文引用的文献
1
Global Distribution of Businesses Marketing Stem Cell-Based Interventions.全球营销基于干细胞的干预措施的企业分布。
Cell Stem Cell. 2016 Aug 4;19(2):158-162. doi: 10.1016/j.stem.2016.07.015.
2
Towards a bioethics of innovation.迈向创新生物伦理学。
J Med Ethics. 2016 Jul;42(7):445-9. doi: 10.1136/medethics-2015-103048. Epub 2016 Mar 25.
3
Therapeutic journeys: the hopeful travails of stem cell tourists.治疗之旅：干细胞游客的满怀希望的艰难历程。
Sociol Health Illn. 2014 Jun;36(5):670-85. doi: 10.1111/1467-9566.12092. Epub 2013 Nov 25.
4
Experimental stem cell therapy: biohierarchies and bionetworking in Japan and India.实验性干细胞治疗：日本和印度的生物层次结构和生物网络。
Soc Stud Sci. 2011 Oct;41(5):645-66. doi: 10.1177/0306312711409792.
Zotero 插件